Company News-Bio-Thera Solutions, Ltd.

2025-08-26

Guangzhou, China– August , 2024 – Inc. “The EC approval of BAT2206 is anothersignificant accomplishment for Bio-Thera as...

查看详情

01-242022

Bio-Thera Solutions Announces First Patient Dosed in Australia for BAT6021, an ADCC-enhanced Monoclonal Antibody Targeting TIGIT for the Treatment of Solid Tumors

Guangzhou, China--(BUSINESSWIRE)-- Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceuticalcompany, tod...
12-302021

Bio-Thera Solutions Announces Initiation of Phase I Clinical Trials for BAT6026, a Monoclonal Antibody Targeting OX40

Guangzhou, China --(BUSINESSWIRE)-- Bio-TheraSolutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, to...
12-302021

Bio-Thera Solutions Announces Initiation of Phase I Clinical Trials for BAT6005, a Monoclonal Antibody Targeting TIGIT

Guangzhou, China --(BUSINESSWIRE)-- Bio-TheraSolutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, to...